These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 18477663)

  • 21. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
    McKeage K; Cheer S; Wagstaff AJ
    Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR.
    Schopohl J; Strasburger CJ; Caird D; Badenhoop K; Beuschlein F; Droste M; Plöckinger U; Petersenn S;
    Exp Clin Endocrinol Diabetes; 2011 Mar; 119(3):156-62. PubMed ID: 21086246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
    Caron P; Beckers A; Cullen DR; Goth MI; Gutt B; Laurberg P; Pico AM; Valimaki M; Zgliczynski W
    J Clin Endocrinol Metab; 2002 Jan; 87(1):99-104. PubMed ID: 11788630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatostatin agonists for treatment of acromegaly.
    Ben-Shlomo A; Melmed S
    Mol Cell Endocrinol; 2008 May; 286(1-2):192-8. PubMed ID: 18191325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lanreotide Autogel: a review of its use in the management of acromegaly.
    Croxtall JD; Scott LJ
    Drugs; 2008; 68(5):711-23. PubMed ID: 18370450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients.
    van Thiel SW; Romijn JA; Biermasz NR; Ballieux BE; Frölich M; Smit JW; Corssmit EP; Roelfsema F; Pereira AM
    Eur J Endocrinol; 2004 Apr; 150(4):489-95. PubMed ID: 15080778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lanreotide autogel in acromegaly - a decade on.
    Kyriakakis N; Chau V; Lynch J; Orme SM; Murray RD
    Expert Opin Pharmacother; 2014 Dec; 15(18):2681-92. PubMed ID: 25307803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A single-center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide Autogel in patients with acromegaly previously treated with octreotide.
    Kelly P; Maher KT; Chew SL; Monson JP; Grossman AB; Jenkins PJ
    Endocr Pract; 2010; 16(2):191-7. PubMed ID: 19833584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
    Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
    Yang LP; Keating GM
    Drugs; 2010 Sep; 70(13):1745-69. PubMed ID: 20731479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly.
    Tutuncu Y; Berker D; Isik S; Ozuguz U; Akbaba G; Kucukler FK; Aydin Y; Guler S
    Pituitary; 2012 Sep; 15(3):398-404. PubMed ID: 21863263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Slow-release lanreotide and octreotide LAR in the medical therapy of acromegaly.
    Giusti M; Sessarego P; Timossi G; Bocca L
    Eur J Endocrinol; 2000 Jun; 142(6):697-8. PubMed ID: 10822235
    [No Abstract]   [Full Text] [Related]  

  • 33. Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors.
    Ludlam WH; Anthony L
    Adv Ther; 2011 Oct; 28(10):825-41. PubMed ID: 21964965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study.
    Neggers SJ; Pronin V; Balcere I; Lee MK; Rozhinskaya L; Bronstein MD; Gadelha MR; Maisonobe P; Sert C; van der Lely AJ;
    Eur J Endocrinol; 2015 Sep; 173(3):313-23. PubMed ID: 26047625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Somatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patients].
    Caron P
    Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 3):2S19-24. PubMed ID: 12037499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lanreotide autogel(®): a review of its use in the treatment of patients with acromegaly.
    Burness CB; Dhillon S; Keam SJ
    Drugs; 2014 Sep; 74(14):1673-91. PubMed ID: 25193626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of long-acting somatostatin analogues in acromegaly.
    Jenkins PJ
    Growth Horm IGF Res; 2000 Apr; 10 Suppl B():S111-4. PubMed ID: 10984265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.
    Mazziotti G; Giustina A
    Pituitary; 2010; 13(1):60-7. PubMed ID: 19189218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly.
    al-Maskari M; Gebbie J; Kendall-Taylor P
    Clin Endocrinol (Oxf); 1996 Oct; 45(4):415-21. PubMed ID: 8959079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.